Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 6, 2011, Pages 997-1003

  Gu, Liu Fang ^a   Zhang, Wang Gang ^a   Wang, Fang Xia ^a   Cao, Xing Mei ^a   Chen, Yin Xia ^a   He, Ai Li ^a   Liu, Jie ^a   Ma, Xiao Rong ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

G CSF priming; HAG regimen; HHT; Low dose chemotherapy; Mechanisms; Refractory relapsed acute myeloid leukemia

Indexed keywords

CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANAL INFECTION; ANUS DISEASE; APPENDICITIS; ARTICLE; BILIARY TRACT INFECTION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SEPTICEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECEPTORS, CXCR4; RECURRENCE;

EID: 79959702661     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0947-z     Document Type: Article

References (43)

1. Bai A et al (1999) Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 27(2):259-265 (Pubitemid 29131737)
2. Bennett JM et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103(4):620-625
3. Camera A, Rinaldi CR et al (2009) Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients. Ann Hematol 88(2):151-158
4. Cephalotaxine Esters in the Treatment of Acute Leukemia (1976) A preliminary clinical assessment. Chin Med J (Engl). 2(4):263-72
5. De La Luz Sierra M et al (2007) Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells. Blood 110(7):2276-2285
6. de la Rubia J, Regadera A, Martín G et al (2002) FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res 26(8):725-730 (Pubitemid 34628370)
7. Erba HP, Kantarjian H, Claxton DF et al (2008) Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy. Blood 112(209) (abstr 558)
8. Faderl S et al (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-947 (Pubitemid 40170859)
9. Fanucchi MP, KongXR, Chou TC (1986) Hexamethylene bisacetamide(HMBA) does not enhance the cytotoxic effects of adriamycin (ADR), 1,b-D- arabinofuranosylcytosine(Ara-C) and harringtonine (HT) in HL-60 cells. Proc Am Assoc Cancer Res 27:(376) (abstract 1492)
10. Feldman E et al (1992) Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 6(11):1189-1191
11. Fiedler Wet al (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3):986-993
12. Fresno M, Jimenez A, Vazquez D (1977) Inhibition of translation in eukaryotic systems by harringtonine.Eur JBiochem72(2):323-330
13. Hamblin TJ (1995) 1st International Conference on Reversal of Multidrug Resistance in Cancer. St. Gallen, Switzerland, 1-3 September 1994. Leuk Res 19(6):427-428
14. Hanel M, Friedrichsen K et al (2001) Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia. Onkologie 24(4):356-360 (Pubitemid 34701520)
15. Hofmann WK et al (2004) Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 83(8):498-503 (Pubitemid 39144750)
16. Huang MT (1975) Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11(5):511-519
17. Jackson G, Taylor P et al (2001) A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 112(1):127-137 (Pubitemid 32151160)
18. Kantarjian HM et al (1989) Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63(5):813-817 (Pubitemid 19063182)
19. Kern W, Schoch C et al (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 14(2):226-231 (Pubitemid 30095375)
20. Legha SS et al (1984) Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68(9):1085-1091 (Pubitemid 14027401)
21. Levy V et al (2006) A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. Br J Cancer 95(3):253-259 (Pubitemid 44187584)
22. Li YH et al (1983) Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children. Chin Med J (Engl) 96(4):303-305
23. Li JM, Shen Y et al (2005) Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 82(1):48-54 (Pubitemid 41512199)
24. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood. N Engl J Med 324:808-815
25. List AF, Kopecky KJ et al (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest oncology group study. Blood 98(12):3212-3220
26. Lowenberg B, Burnett AK (2005) Acute myeloid leukemia in adults. In: Degos L, Linch DC, Lowenberg B (eds) Textbook of malignant hematology. London: Taylor & Francis, p 645
27. Mai WY, Lin MF (2005) Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J (Engl) 118(6):487-492
28. Mao YQ, Li XR, Lei S (2006) Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line. Zhong guo Shi Yan Xue Ye Xue Za Zhi 14(4):681-685
29. O'Brien S et al (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86(9):3322-3326
30. Ohno R, Naoe T et al (1994) A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 83(8):2086-2092 (Pubitemid 24112719)
31. Qian SX, Li JY, Tian T, Shen YF et al (2007) Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res (10):1383-1388. Epub 2007 Apr 8 (Pubitemid 47212427)
32. Rombouts EJ et al (2004) Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 104(2):550-557
33. Saito K et al (2000) Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 71(3):238-244
34. Semerad CL et al (2005) G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 106(9):3020-3027 (Pubitemid 41565894)
35. Smith CR Jr, Powell RG, Mikolajczak KL (1976) The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep 60(8):1157-1170
36. Spoo AC, Wierda WG, Burger JA (2004) The CXCR4 score: a new prognostic marker in acute myelogenous leukemia [abstract]. Blood 104:304a
37. Sugiyama T et al (2006) Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25(6):977-988 (Pubitemid 44894948)
38. Takemura Y et al (1985) Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 14(3):206-210 (Pubitemid 15118639)
39. Warrell RP Jr, Coonley CJ, Gee TS (1985) Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 3(5):617-621 (Pubitemid 15119231)
40. Yamada K et al (1995) Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 9(1):10-14
41. Ye XJ, Lin MF (2004) Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 5(2):230-234
42. Zhang ZY et al (1987) Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases. Chin Med J (Engl) 100(7):565-568
43. Zhou JY et al (1990) Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 50(7):2031-2035